Home>>Signaling Pathways>> Others>> Imidazoline Receptors>>Moxonidine hydrochloride
Moxonidine hydrochloride Catalog No.GC11198

Mixed I1 imidazoline receptor and α2-adrenergic agonist

Size Price Stock Qty
In stock
In stock

Customer Review

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:

Chemical Properties

Cas No. 75536-04-8 SDF
Chemical Name 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine;hydrochloride
Canonical SMILES CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC.Cl
Formula C9H13Cl2N5O M.Wt 278.14
Solubility Soluble in DMSO Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • Molarity Calculator

  • Dilution Calculator

**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).



Moxonidine hydrochloride is a mixed agonist of α2-adrenergic receptor (α2AR) and imidazoline-1 receptor(I1R) with Ki values of 4.2±3.2 nmol/L, 13.0±4.2 nmol/L, 9.5±4.1 nmol/L and 15.6±9.8 nmol/L for I1R, α2AAR, α2BAR andα2CAR, respectively [1].

In multiple acute pain assays, moxonidine has been reported to produce dose-dependent analgesia.In both the α2AAR-dysfunctional and α2CAR-KO experimentsin mice, the rest analgesia function of moxonidine has been revealed to be mediated by α2ARs but not I1Rs [1]. In addition, Moxonidine has been reported to potently inhibit the binding of [3H]-clonidine to VLM (ventrolateral medulla) membranes in a dose-dependent manner with the IC50 value of 53 ± 10nM. In bovine adrenal medullary cells, Moxonidine has shown low affinity for I2-relative to I1R sites [2].

[1]Stone LS1, Fairbanks CA, Wilcox GL. Moxonidine, a mixed alpha(2)-adrenergic and imidazoline receptor agonist, identifies a novel adrenergic target for spinal analgesia. Ann N Y Acad Sci. 2003 Dec;1009:378-85.
[2]Ernsberger P1, Damon TH, Graff LM, Schäfer SG, Christen MO.Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites. J Pharmacol Exp Ther. 1993 Jan;264(1):172-82.